Rakovina Therapeutics Inc Total Assets
Rakovina Therapeutics Inc total assets. Based on the latest financial reports, Rakovina Therapeutics Inc (RKV) holds total assets worth CA$5.27 Million CAD (≈ $3.81 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see RKV market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Rakovina Therapeutics Inc (2021–2024)
Total assets of Rakovina Therapeutics Inc from 2021 to 2024. This chart illustrates how Rakovina Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See today's stock price for Rakovina Therapeutics Inc for real-time trading data and today's change.
Rakovina Therapeutics Inc - Asset Composition Analysis
Rakovina Therapeutics Inc Total Assets Breakdown (December 2024)
Rakovina Therapeutics Inc total assets breakdown as of December 2024. Rakovina Therapeutics Inc's total assets of CA$5.27 Million consist of 36.3% current assets and 63.7% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 21.0% |
| Accounts Receivable | CA$81.33K | 1.3% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$3.98 Million | 63.7% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Rakovina Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Rakovina Therapeutics Inc working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Rakovina Therapeutics Inc's current assets represent 36.3% of total assets in 2024, an increase from 35.5% in 2021.
- Cash Position: Cash and equivalents constituted 21.0% of total assets in 2024, down from 32.5% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 63.0% of total assets, a decrease from 64.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 63.7% of total assets.
Rakovina Therapeutics Inc Competitors by Total Assets
Key competitors of Rakovina Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Rakovina Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.78 | 1.43 | 14.87 |
| Quick Ratio | 0.78 | 1.43 | 14.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-489.28K | CA$358.06K | CA$4.48 Million |
Rakovina Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Rakovina Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.96 |
| Latest Market Cap to Assets Ratio | 0.43 |
| Asset Growth Rate (YoY) | 21.2% |
| Total Assets | CA$6.24 Million |
| Market Capitalization | $2.68 Million USD |
Valuation Analysis
Below Book Valuation: The market values Rakovina Therapeutics Inc's assets below their book value (0.43x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Rakovina Therapeutics Inc's assets grew by 21.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Rakovina Therapeutics Inc (2021–2024)
The table below shows the annual total assets of Rakovina Therapeutics Inc from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CA$6.24 Million ≈ $4.51 Million |
+21.24% |
| 2023-12-31 | CA$5.15 Million ≈ $3.72 Million |
-15.90% |
| 2022-12-31 | CA$6.12 Million ≈ $4.43 Million |
-29.31% |
| 2021-12-31 | CA$8.66 Million ≈ $6.26 Million |
-- |
About Rakovina Therapeutics Inc
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series … Read more